Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | ICMT | O60725 | 2/20 | 0.43 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29718576 | 0.84 | CTBP2 (0.55) | CTBP2MAPK8TAAR1PTGS2HPGD | |
| SCHEMBL158861 | 0.84 | CTBP2 (0.55) | CTBP2MAPK8TAAR1PTGS2HPGD | |
| SCHEMBL9447453 | 0.83 | PTGS2 (0.54) | FFAR1FFAR4CTBP2MYCPTGS2 | |
| SCHEMBL12265632 | 0.82 | CHRM1 (0.46) | ICMTALDH1A1MAPT | |
| SCHEMBL9890744 | 0.82 | SLC9A1 (0.41) | ICMTSLC9A1MAPT | |
| Hydrochloric Acid SCHEMBL14167478 | 0.82 | CTBP2 (0.53) | CTBP2MAPK8TAAR1PTGS2HPGD | |
| SCHEMBL15866818 | 0.81 | TAAR1 (0.38) | FFAR1FFAR4CTBP2MYCIKBKB | |
| SCHEMBL339508 | 0.81 | P2RX7 (0.44) | ICMTCTBP2MAPK8PTGS2ALDH1A1 | |
| SCHEMBL18302007 | 0.80 | PTGS2 (0.44) | ICMTMYCPTGS2ALDH1A1MEN1 | |
| SCHEMBL9890740 | 0.80 | PTGDR2 (0.46) | ICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | FFAR1 223/4885FFAR4 621/4885ICMT 2894/4885 |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | FFAR1 223/4885FFAR4 621/4885ICMT 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.